Overview

Study of Human Insulin Inhalation Powder in Patients With Type 2 Diabetes

Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
0
Participant gender:
All
Summary
This is a phase 3, open-label, randomized study to evaluate the safety and efficacy of the Lilly/Alkermes inhaled insulin system compared to injected pre-meal insulin in non-smoking patients with type 2 diabetes. Patients will be treated for 24 months with a 2-month follow-up period.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Eli Lilly and Company
Collaborator:
Alkermes, Inc.
Treatments:
Insulin
Insulin, Globin Zinc
Criteria
Inclusion Criteria:

- Type 2 diabetes

- Non smoker

- Normal lung function

Exclusion Criteria:

- Pulmonary, hepatic, or renal disease

- Congestive heart failure

- Active malignancy

- Systemic glucocorticoid therapy